Danish Construction Stock News

CPSE:VWS
CPSE:VWSElectrical

How Vestas’ Vanguard West Offshore Win Will Impact Vestas Wind Systems (CPSE:VWS) Investors

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...
CPSE:GMAB
CPSE:GMABBiotechs

Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness

What Genmab’s recent share performance may be telling investors Genmab (CPSE:GMAB) has seen its share price slip about 10% over the past month and roughly 9% over the past 3 months, which may prompt investors to reassess the biotech’s current valuation. See our latest analysis for Genmab. While the share price is around DKK1,848.5 and the 30 day and 90 day share price returns are both close to a 10% decline, the 1 year total shareholder return of about 15% alongside a weaker 3 year total...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Is Novo Nordisk (CPSE:NOVO B) Recasting Its Obesity Strategy After CagriSema Trails Zepbound?

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...
CPSE:RBREW
CPSE:RBREWBeverage

Royal Unibrew (CPSE:RBREW) Margins At 9.9% TTM Support Gradual Profitability Narrative

Royal Unibrew (CPSE:RBREW) has wrapped up FY 2025 with fourth quarter revenue of DKK 3.8b and basic EPS of DKK 7.0, alongside net income of DKK 345m, setting the tone for how the full year filters through to margins. The company has seen quarterly revenue move from DKK 3.6b and EPS of DKK 4.6 in Q4 2024 to DKK 3.8b and EPS of DKK 7.0 in Q4 2025, with trailing twelve month EPS at DKK 31.4 and net income at DKK 1.6b framing a year where profitability sits at the center of the story for...
CPSE:AOJ B
CPSE:AOJ BTrade Distributors

Brødrene A & O Johansen (CPSE:AOJ B) Margin Uptick Challenges Long Term Bearish Earnings Narrative

Brødrene A & O Johansen (CPSE:AOJ B) closed FY 2025 with Q4 revenue of DKK1.7 billion and basic EPS of DKK3.01, against a backdrop of trailing 12 month EPS of DKK7.4 and net income of DKK200.7 million that sits alongside 22.8% earnings growth over the past year. Over recent periods the company has seen revenue move from DKK5.4 billion on a trailing 12 month basis in Q4 2024 to DKK6.1 billion in Q4 2025. Over the same timeframe, trailing EPS shifted from DKK6.01 to DKK7.4, setting up a story...
CPSE:TCM
CPSE:TCMConsumer Durables

TCM Group (CPSE:TCM) Net Margin Lift To 6.1% Tests Quality Of Earnings Narratives

TCM Group (CPSE:TCM) has wrapped up FY 2025 with fourth quarter revenue of DKK 333.1 million and basic EPS of DKK 3.27, alongside trailing twelve month EPS of DKK 7.51 on revenue of DKK 1.28b and net income of DKK 77.77 million. Over recent periods, the company has seen quarterly revenue move from DKK 301.4 million and EPS of DKK 2.20 in Q4 2024 to DKK 333.1 million and EPS of DKK 3.27 in Q4 2025. Interim quarters ranged between DKK 277.7 million and DKK 349.1 million of revenue, with EPS...
CPSE:DEMANT
CPSE:DEMANTMedical Equipment

Assessing Demant’s (CPSE:DEMANT) Valuation After US VA Gains And Expanded Cost Cuts

Why Demant (CPSE:DEMANT) Is Back in Focus for Investors Demant (CPSE:DEMANT) is drawing fresh attention after gaining market share in the US Veterans Affairs hearing aid channel, while at the same time expanding cost saving layoffs at its Danish operations. See our latest analysis for Demant. The recent gain in US Veterans Affairs market share and the expanded cost-saving program comes after a mixed price pattern, with an 8.07% 7-day share price return, a 30-day share price return of 11.11%,...
CPSE:TRMD A
CPSE:TRMD AOil and Gas

TORM (CPSE:TRMD A) Margin Compression Reinforces Bearish Earnings Narrative Despite Solid Q4 EPS

TORM (CPSE:TRMD A) has just posted its FY 2025 numbers with fourth quarter revenue of US$352.6 million and basic EPS of US$0.88, while trailing twelve month revenue came in at about US$1.3 billion and EPS at US$2.91. The company has seen quarterly revenue move from US$305.4 million in Q4 2024 to US$352.6 million in Q4 2025, with basic EPS shifting from US$0.81 to US$0.88 over the same period, setting up the latest release against a backdrop of tighter net profit margins and mixed earnings...
CPSE:ISS
CPSE:ISSCommercial Services

Assessing ISS (CPSE:ISS) Valuation As Share Price Consolidates After Mixed Recent Returns

Why ISS (CPSE:ISS) Is On Investors’ Radar Today ISS (CPSE:ISS) is drawing attention after recent share price moves, with a flat 1 day return but a 7 day decline of 7.46% and mixed performance over the past month and past 3 months. See our latest analysis for ISS. While the recent 7 day share price return of 7.46% decline suggests fading short term momentum, the 1 year total shareholder return of 42.28% and 5 year total shareholder return of 114.76% point to a much stronger longer term picture...
CPSE:ALSYDB
CPSE:ALSYDBBanks

Sydbank (CPSE:ALSYDB) Q4 EPS Loss Challenges Bullish Earnings Growth Narratives

Sydbank (CPSE:ALSYDB) has wrapped up FY 2025 with Q4 revenue of DKK 3.2b and a basic EPS loss of DKK 0.64, capping off a year in which trailing 12 month revenue sits at DKK 8.4b and basic EPS at DKK 35.03. Over recent quarters, revenue has moved from DKK 1.6b in Q4 2024 to between DKK 1.7b and DKK 1.9b through the first three quarters of 2025. Quarterly EPS has ranged from DKK 6.88 to DKK 14.31 before the latest loss, which is prompting a debate among investors about how durable the bank’s...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

A Look At ALK Abelló (CPSE:ALK B) Valuation As Recent Momentum Slows

Recent share performance and business profile ALK-Abelló (CPSE:ALK B) has drawn investor attention after a period where the share price showed mixed short term performance, with a modest move over the past day contrasting with weaker recent weekly and monthly returns. The Denmark based allergy solutions company focuses on immunotherapy treatments, diagnostic products, emergency medicine for severe allergic reactions, and digital tools that support patients in managing respiratory and food...
CPSE:NSIS B
CPSE:NSIS BChemicals

Assessing Novozymes (CPSE:NSIS B) Valuation After Strong 2025 Results And Dividend Increase

Why Novozymes stock is back on investors’ radar Novozymes (CPSE:NSIS B), now operating as Novonesis, has caught investor attention after reporting 7% organic sales growth, a 37.1% adjusted EBITDA margin for 2025, and proposing a higher dividend. The company’s board has also called an Annual General Meeting for March 23, 2026. At this meeting, shareholders will vote on dividend plans, board re-elections, and a bylaw change governing where physically attended general meetings can be held in...
CPSE:NKT
CPSE:NKTElectrical

NKT (CPSE:NKT) Margin Uptick To 7.4% Tests Bullish Profitability Narratives

NKT (CPSE:NKT) has just wrapped up FY 2025 with fourth quarter revenue of €847 million, basic EPS of €1.77 and net income of €94 million, setting the tone for how the full year is being read by the market. Over the past six quarters, the company has seen quarterly revenue move between €837 million and €945 million while basic EPS ranged from €0.95 to €1.77. On a trailing twelve month basis EPS came in at €4.93 with net income of €264 million, giving investors a clear view of the earnings run...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Reassessing Novo Nordisk (CPSE:NOVO B) After Sharp Share Price Declines

If you are looking at Novo Nordisk and wondering whether the current share price still lines up with the company’s long term story, you are not alone. The stock last closed at DKK 238.6, with returns of 22.4% decline over 7 days, 39.4% decline over 30 days, 27.8% decline year to date, 61.8% decline over 1 year and 50.0% decline over 3 years, while the 5 year return stands at 19.6%. These swings have arrived alongside ongoing attention on Novo Nordisk’s role in diabetes and weight management...
CPSE:NETC
CPSE:NETCIT

Assessing Netcompany Group (CPSE:NETC) Valuation After New DKK 750m Share Buyback Programme

Why Netcompany Group’s new buyback matters for shareholders Netcompany Group (CPSE:NETC) has put a fresh DKK 750m share buyback programme in place, targeting up to 3,250,000 shares in order to reshape its capital structure and cover share-based incentive commitments. See our latest analysis for Netcompany Group. Netcompany’s new buyback follows a short burst of positive momentum, with a 1-day share price return of 3.25% and a 7-day share price return of 2.71%. This comes against a weaker...
CPSE:NORTHM
CPSE:NORTHMMedia

North Media (CPSE:NORTHM) Margin Compression To 4.2% Reinforces Bearish Profitability Narratives

North Media (CPSE:NORTHM) FY 2025 headline numbers North Media (CPSE:NORTHM) has wrapped up FY 2025 with Q4 revenue of DKK356.8 million and basic EPS of DKK1.73, alongside trailing twelve month revenue of DKK1.296 billion and EPS of DKK3.02. Over recent quarters, revenue has moved from DKK343.1 million in Q2 2024 to DKK310.5 million in Q1 2025 and then to DKK356.8 million in Q4 2025. Quarterly EPS has swung from a loss of DKK6.87 in Q1 2025 to a profit of DKK5.29 in Q2 and DKK1.73 in Q4. With...
CPSE:JDAN
CPSE:JDANReal Estate

Assessing Jeudan (CPSE:JDAN) Valuation After Strong 2025 Earnings And Dividend Confirmation

Jeudan (CPSE:JDAN) has just released its full year 2025 results, reporting sales of DKK 1,751.36 million and net income of DKK 1,000.45 million, alongside an affirmed annual dividend of DKK 3.00 per share. See our latest analysis for Jeudan. Jeudan's latest earnings and dividend affirmation come after a steady build in momentum, with a 30 day share price return of 2.5% and a 4.1% total shareholder return over the past year, even though the 3 year total shareholder return of 14.9% decline...
CPSE:DSV
CPSE:DSVLogistics

Assessing DSV (CPSE:DSV) Valuation As Ship Green Agreement Puts Sustainability In The Spotlight

DSV (CPSE:DSV) is back in focus after signing a two year Ship Green framework agreement with Hapag Lloyd. The agreement targets 18,000 tonnes of CO₂e emission reductions through sustainable marine fuels in ocean freight. See our latest analysis for DSV. The Ship Green deal comes as DSV’s 90 day share price return of 10.88% contrasts with a softer 30 day share price return of 6.90% and a 12 month total shareholder return of 12.99%. This suggests earlier momentum has cooled recently while...
CPSE:JYSK
CPSE:JYSKBanks

Jyske Bank’s Multi Year Buyback Puts Capital Returns In Focus

Jyske Bank (CPSE:JYSK) has launched a substantial share repurchase programme. The buyback is scheduled to run until January 2027. The programme focuses on returning capital to shareholders through share repurchases over a multi year period. Jyske Bank is a major Danish financial institution, so a large scale buyback can be an important signal for investors following the Nordic banking sector. Banks globally have been adjusting capital plans, focusing on balance sheet strength, regulatory...
CPSE:TRMD A
CPSE:TRMD AOil and Gas

Assessing TORM (CPSE:TRMD A) Valuation After Strong Recent Share Price Gains

Recent performance snapshot for TORM (CPSE:TRMD A) TORM (CPSE:TRMD A) has attracted fresh attention after a period of strong share price performance, with the stock up around 22% over the past month and 27% over the past 3 months. See our latest analysis for TORM. The recent momentum fits into a broader upswing, with a 39.26% year to date share price return and a 43.04% total shareholder return over the past year indicating that buyers have been willing to pay more for TORM over time. If this...
CPSE:PAAL B
CPSE:PAAL BConstruction

Assessing Per Aarsleff Holding (CPSE:PAAL B) Valuation After New Canadian LiquiForce Partnership

Why the new Canadian partnership matters for Per Aarsleff Holding Per Aarsleff Holding (CPSE:PAAL B) recently became a part owner in a new LiquiForce partnership within the PURIS group, aiming to expand lateral rehabilitation services for Canadian municipalities and utilities using advanced pipe renewal technologies. See our latest analysis for Per Aarsleff Holding. The Canadian LiquiForce partnership announcement and the recent first quarter results, with sales of DKK 6,180 million and net...
CPSE:COLO B
CPSE:COLO BMedical Equipment

Is Coloplast (CPSE:COLO B) Starting To Look Attractive After A Prolonged Share Price Slump

If you are wondering whether Coloplast shares are starting to look interesting at around kr.482, or if the market is still asking too much for the stock, you are not alone. The share price has slipped 0.5% over the past week, 10.7% over the last month, and 10.1% year to date, adding to a 35.4% decline over 1 year and 39.5% over 5 years that may lead many holders to reassess the balance of risk and opportunity. These price moves sit against a backdrop where investors are reacting to broader...
CPSE:ALSYDB
CPSE:ALSYDBBanks

Assessing AL Sydbank (CPSE:ALSYDB) Valuation After Recent Share Price Move

Why AL Sydbank is on investors’ radar today AL Sydbank (CPSE:ALSYDB) has drawn fresh attention after its recent share move, with the stock up 4.96% over the past day and modestly higher over the past week and month. See our latest analysis for AL Sydbank. That 1-day share price return of 4.96% comes after a softer year to date, with the share price return down 1.67%. Over the longer term, the 5-year total shareholder return of 369.28% points to strong historical rewards and suggests recent...
CPSE:CARL B
CPSE:CARL BBeverage

Carlsberg India IPO Exploration Raises New Questions On Growth And Valuation

Carlsberg is preparing for a potential IPO of its India unit and has appointed major banks as advisers. The move would separate part of its India operations into a listed entity, subject to market conditions and internal approvals. The company has not yet announced a timetable or size for the potential offering. For investors tracking CPSE:CARL B, the India IPO preparation comes as the share price stands at DKK971.6. The stock is up 14.2% over the past 30 days, 17.7% year to date, and 12.3%...